Issue Date: November 1, 2010
GSK Collaborates With Amicus On A Rare Disease
Under the terms of the agreement, GSK will receive an exclusive worldwide license to develop, manufacture, and commercialize migalastat. The two companies will also launch new clinical studies on coadministration of migalastat with enzyme replacement therapy for treatment of the disease.
Fabry disease is a rare . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society